Candel Therapeutics, a pioneering clinical stage biopharmaceutical company, has announced a significant funding milestone, successfully raising $52 million to advance its innovative cancer immunotherapy initiatives. Candel is at the forefront of developing off-the-shelf multimodal biological treatments designed to generate an individualized and systemic anti-tumor immune response, offering new hope to patients battling cancer. With cutting-edge platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, Candel is diligently working to bring next-generation therapies to clinical practice. The exciting lead candidate from the HSV platform, CAN-3110, is currently undergoing an investigator-sponsored phase 1 clinical trial aimed at addressing recurrent high-grade glioma (HGG). In line with this, Candel’s enLIGHTEN™ Discovery Platform utilizes human biology and advanced analytics to innovate new viral immunotherapies targeting solid tumors. Meanwhile, CAN-2409, the flagship candidate from the adenovirus platform, is making strides in various phases of clinical trials for non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized prostate cancer. The funds raised will be strategically allocated towards accelerating these trials and enhancing research capabilities, further solidifying Candel’s commitment to transforming cancer treatment. As the company innovates at the intersection of biotechnology and patient care, they invite interested parties to learn more about their promising journey by visiting www.candeltx.com or reaching out via email at info@candeltx.com.
Candel ($CADL) Secures $52M in Funding to Advance Revolutionary Cancer Immunotherapies
Recently funded · $52.0MHealthcare
Get the full Tasca Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
